Cumberland Pharma

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cumberland Pharma reports steady Q1 performance amidst sales challenges

Cumberland Pharma's Q1 2024 performance showcased resilience in the face of sales challenges, with a strategic emphasis on FDA-approved brands. The company's dedication to innovation and patient care underpins its growth trajectory, despite hurdles posed by insurance deductibles.

Cumberland Pharma reports revenue growth but faces profitability challenges

Cumberland Pharmaceuticals demonstrated revenue growth potential but grappled with profitability challenges in Q2 2024. The company's focus on innovation, market expansion, and patient care underscores a commitment to long-term success. Addressing cost management, profitability, and leveraging growth opportunities will be crucial for Cumberland's future.

Cumberland Pharma reports resilient Q3 performance amidst operational challenges

Cumberland Pharma's Q3 2024 performance was driven by FDA-approved brands despite challenges.
The company showcased improved financials with a focus on operational efficiency and growth opportunities.
While facing challenges like product returns and expenses, Cumberland maintains a strong financial position.
Strategic initiatives and research efforts position Cumberland for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A.

Cumberland (CPIX) delivered earnings and revenue surprises of 166.67% and 3.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Q2 Earnings and Revenues Beat Estimates

Shares of Cumberland (NASDAQ:CPIX) rose 2.07% in after-market trading after the company reported Q2 results.

Cumberland: Q2 Earnings Insights

NASHVILLE, Tenn., Aug. 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update

NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results

NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Cumberland (CPIX) Rating Upgrade to Buy

NASHVILLE, Tenn., May 26, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia...

New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis

Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Miss Estimates

NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results. Net revenues from...

Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cumberland Pharmaceuticals (CPIX) to Report a Decline in Earnings: What to Look Out for

AMAG Pharmaceuticals

Milestone Pharmaceuticals Inc

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

3 Drugmakers Still Worth Betting on Amid Coronavirus Woes

Alimera Sciences

Overseas Shipholding Group

Roadrunner Transportation

Titan Pharma

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Penny Stocks to Buy Using Technical Analysis for April 2020

Cumberland Pharmaceuticals Inc (CPIX) CEO A. J. Kazimi on Q4 2019 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of 800.00% and 20.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Q4 Earnings and Revenues Beat Estimates

Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q4 Earnings Expected to Decline

Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q3 2019 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of -90.91% and -18.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Misses Q3 Earnings and Revenue Estimates

Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.

Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?

Cumberland Pharmaceuticals (CPIX) to Report Q3 Results: Wall Street Expects Earnings Growth

Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.

Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know

Cumberland Pharmaceuticals (CPIX) closed at $5.30 in the latest trading session, marking a -1.6% move from the prior day.

Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know

Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

News for Cumberland Pharma Stock (CPIX)